Abstract
Borderline Personality Disorder (BPD) is a common disorder in psychiatric practice and drugs are widely used in its treatment, targeting symptom clusters, such as affective dysregulation, impulsive-behavioural dyscontrol, and cognitive-perceptual symptoms. In last period, a growing number of studies on pharmacological treatment of BPD have been performed, but different proposals of treatment guidelines are not completely in accordance on drug indications for BPD patients. This article reviews double-blind randomized controlled trials comparing active drugs versus placebo and drugs versus drugs, published between 1990 and 2010 and focused on the treatment of borderline personality disorder. Different classes of psychoactive agents, such as antipsychotics, mood stabilizers, antidepressants, and dietary supplementation were tested in BPD patients. More recent evidences suggest that mood stabilizers (topiramate, valproate and lamotrigine), second generation antipsychotics (olanzapine and aripiprazole) and omega-3 fatty acids can be useful to treat affective symptoms and impulsive-behavioural dyscontrol in BPD patients. Moreover, antipsychotics significantly improve cognitive symptoms in patients with BPD. SSRIs were found effective in decreasing severity of depressed mood, anxiety and anger, mainly in subjects with a concomitant affective disorder. Effects of antidepressants on impulsive behaviours are uncertain. Further studies are needed to improve methods of trials and confirm these findings.
Keywords: Borderline personality disorder, pharmacotherapy, antidepressants, antipsychotics, mood stabilizers, omega-3 fatty acids, randomized controlled trials, efficacy, adverse effects, treatment guidelines
Current Medicinal Chemistry
Title: Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Volume: 18 Issue: 22
Author(s): S. Bellino, C. Rinaldi, P. Bozzatello and F. Bogetto
Affiliation:
Keywords: Borderline personality disorder, pharmacotherapy, antidepressants, antipsychotics, mood stabilizers, omega-3 fatty acids, randomized controlled trials, efficacy, adverse effects, treatment guidelines
Abstract: Borderline Personality Disorder (BPD) is a common disorder in psychiatric practice and drugs are widely used in its treatment, targeting symptom clusters, such as affective dysregulation, impulsive-behavioural dyscontrol, and cognitive-perceptual symptoms. In last period, a growing number of studies on pharmacological treatment of BPD have been performed, but different proposals of treatment guidelines are not completely in accordance on drug indications for BPD patients. This article reviews double-blind randomized controlled trials comparing active drugs versus placebo and drugs versus drugs, published between 1990 and 2010 and focused on the treatment of borderline personality disorder. Different classes of psychoactive agents, such as antipsychotics, mood stabilizers, antidepressants, and dietary supplementation were tested in BPD patients. More recent evidences suggest that mood stabilizers (topiramate, valproate and lamotrigine), second generation antipsychotics (olanzapine and aripiprazole) and omega-3 fatty acids can be useful to treat affective symptoms and impulsive-behavioural dyscontrol in BPD patients. Moreover, antipsychotics significantly improve cognitive symptoms in patients with BPD. SSRIs were found effective in decreasing severity of depressed mood, anxiety and anger, mainly in subjects with a concomitant affective disorder. Effects of antidepressants on impulsive behaviours are uncertain. Further studies are needed to improve methods of trials and confirm these findings.
Export Options
About this article
Cite this article as:
Bellino S., Rinaldi C., Bozzatello P. and Bogetto F., Pharmacotherapy of Borderline Personality Disorder: A Systematic Review, Current Medicinal Chemistry 2011; 18 (22) . https://dx.doi.org/10.2174/092986711796504682
DOI https://dx.doi.org/10.2174/092986711796504682 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Design, Synthesis and in silico Studies of New 5-substituted-2-(2-(5-aryl- 1H-1, 2, 4-triazole-3-ylthio) acetyl) Hydrazine Carbothioamide/ Carboxamides for Anticonvulsant Activity
Letters in Drug Design & Discovery Connexin Modulators and Their Potential Targets under the Magnifying Glass
Current Medicinal Chemistry Metabotropic Glutamate Receptors in the Trafficking of Ionotropic Glutamate and GABAA Receptors at Central Synapses
Current Neuropharmacology Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Different Food Odors Control Brain Connectivity in Impulsive Children
CNS & Neurological Disorders - Drug Targets The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms
Current Molecular Medicine Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Pharmacological Treatment of Diabetic Peripheral Neuropathy: An Update
CNS & Neurological Disorders - Drug Targets Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research In-vitro Functionality of Clozapine Biphasic Release Minitablet Using Advanced Statistical Tools
Drug Delivery Letters Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design Role of Biotransformation in Conceptal Toxicity of Drugs and Other Chemicals
Current Pharmaceutical Design P-gp Transporter and its Role in Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry